Navigation Links
Data Presented at SLEEP 2007 Shows VEC-162 Improves Sleep Onset and,Maintenance vs. Placebo

b site: http://www.vandapharma.com/

Ticker Symbol: (NASDAQ-NMS:VNDA)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:1/14/2014)... 2014 NineSigma , Inc., the leading innovation ... Leadership Summit , May 14-16, 2014 at the Global ... . This is the premier ... breakthrough achievements through open innovation. Participants will learn how ...
(Date:1/14/2014)... PORT WASHINGTON, New York , January 14, ... the leading provider of Closed System Transfer Devices (CSTD) for hazardous drugs, ... sales growth for the fourth straight year.   ... of exposure for pharmacy technicians, pharmacists, nurses and ...
(Date:1/14/2014)... FRANCISCO , Jan. 14, 2014 Spark Therapeutics , ... for its most advanced clinical program, a Phase 3 study for ... gene. Spark,s CEO, Jeffrey D. Marrazzo , is presenting this ... Healthcare Conference in San Francisco . Marrazzo said ...
Breaking Medicine Technology:Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 3
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) ... officials in FDA,s Office of New Drugs (OND), the ... a cardiovascular outcomes trial (CVOT) for Contrave® that would ... 2011. Orexigen believes that these design requirements are reasonable ...
... CLEVELAND, Sept. 20, 2011 Dr. Melisa Estes, who is ... suffer from chronic knee pain. She recently began incorporating a ... nerve stimulation, also known as TENS, sends electrical stimulation to ... signals from reaching the brain, and that reduces pain. ...
Cached Medicine Technology:Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 2Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 3Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 4Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 5Knee Pain Control - No Drugs - Doctor Used 2
(Date:4/17/2014)... A Northwestern University synthetic biology team has created ... create programmable therapeutics that could travel the body ... disease. , Engineering cell-based, biological devices that monitor ... in clinical synthetic biology. However, no existing technology ... a patient,s physiological state and respond in a ...
(Date:4/17/2014)... as many as 10 million older Americans suffer from ... isolation. , However, new research a project that ... for six years found that Internet use among ... more than 30 percent. , "That,s a very strong ... of telecommunication, information studies and media who led the ...
(Date:4/17/2014)... By discovering a new mechanism that allows blood to ... UC Irvine and the Salk Institute have opened the ... stroke-induced brain damage. , A complex and devastating neurological ... primary reason for disability in the U.S. The blood-brain ... blood-borne material into the brain, causing the permanent deficits ...
(Date:4/17/2014)... An international team led by researchers at UC Davis ... plays a key role in cell division, also boosts ... the first time the complex has been shown to ... B1/Cdk1 an excellent target to control cellular energy production, ... was published online today in the journal Developmental ...
(Date:4/17/2014)... and their partners have found that their proprietary microbicide ... of multiple sexually transmitted infections (STIs) in both the ... 2 (HSV-2), and human papillomavirus (HPV). The USAID-funded study ... effective against multiple strains of HIV, and has a ... viruses of at least eight hours prior to exposure. ...
Breaking Medicine News(10 mins):Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... of the University of Pennsylvania reported today that students ... activity are less likely to smoke than their classmates. ... participation extends at least three years beyond graduation. The ... the same level of protection from school sports as ...
... SATELLITE FEED: ... 6:30 PM - 6:45 PM ET ... C-Band ... Downlink Freq: 3980 Horizontal NEWS: Football Legend John Madden ...
... Created by Hospitals from Around the Country Appeal to the ... Contest to Win a Free MRI, MALVERN, Pa., Dec. 6 ... community, but can,t seem to find the time,now,s your chance to ... click of your mouse! The video posting period in Siemens first-ever,"Win ...
... SAN DIEGO, Dec. 6 Neurocrine Biosciences,Inc. (Nasdaq: ... has closed its sale,and leaseback agreement with Veralliance ... by Neurocrine for the properties was,$109 million. Concurrently ... its corporate headquarters for a 12 year term, ...
... on Christmas ... harmony, CINCINNATI, Dec. 6 As they,re searching the ... toys they,think are safe, now parents have a new worry: ... because the unsafe toy they wanted,isn,t under the tree., ...
... Dec. 6 Dr. Belinda Tsao-Nivaggioli,Chief Executive Officer ... http://www.avicenagroup.com ) will be featured in an exclusive ... at 5 p.m. EST. The interview,will be posted ... on December 10., The interview will cover ...
Cached Medicine News:Health News:Participation in organized high school activities lowers risk of smoking 3 years after graduation 2Health News:Participation in organized high school activities lowers risk of smoking 3 years after graduation 3Health News:The Polls are Open! America Votes to Decide Which Hospital is the Most Deserving of Siemens' Newest MRI Technology 2Health News:The Polls are Open! America Votes to Decide Which Hospital is the Most Deserving of Siemens' Newest MRI Technology 3Health News:Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets 2Health News:Concern Over Toy Safety and Disappointed Kids Impacts Holidays for Parents 2Health News:Concern Over Toy Safety and Disappointed Kids Impacts Holidays for Parents 3Health News:WallSt.net Announces Upcoming Interview With CEO of Avicena Group 2
The Panorama Central Station includes bi-directional communication with Datascope bedside monitors, optional 72 hours of disclosure and a touch screen user interface....
... These specialty Eraser instruments have ... surgeon with the right tool for ... introduced a series of 25 gauge ... provide discrete treatment of target tissues ...
... specialty Eraser instruments have been designed ... the right tool for situations requiring ... series of 25 gauge intraocular, bipolar, ... treatment of target tissues for fine-tip ...
Developed in a Microsoft Windows environment, MedInformatix provides physician practices a Computerized Patient Record (CPR) with a Practice Management System (PMS) that is both integrated and design...
Medicine Products: